bicalutamide and Disease Exacerbation

bicalutamide has been researched along with Disease Exacerbation in 83 studies

Research

Studies (83)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (8.43)	18.2507
2000's	48 (57.83)	29.6817
2010's	26 (31.33)	24.3611
2020's	2 (2.41)	2.80

Authors

Authors	Studies
Funahashi, Y; Gotoh, M; Matsukawa, Y; Muramatsu, T; Sassa, N; Yamamoto, A	1
Bouamar, H; Gu, X; Houghton, PJ; Qin, T; Sun, LZ; Wang, B; Wang, Y; Xia, L; Yang, J; Zeballos, C; Zhang, W; Zhou, Y; Zhu, H	1
Cao, H; Chen, L; Feng, Y; Gao, R; Wang, D	1
Barbosa, FG; Buchpiguel, CA; Costa, LB; Dzik, C; Marin, JFG; Nunes, RF; Queiroz, MA	1
Beraldi, E; Crafter, C; Davies, BR; Fazli, L; Gleave, ME; Kim, S; Lamoureux, F; Thaper, D; Thomas, C; Zoubeidi, A	1
Appella, E; Arra, C; Auricchio, F; Castoria, G; Di Donato, M; Giovannelli, P; Hayashi, R; Migliaccio, A	1
Haller, AC; Li, F; Morrison, C; Payne-Ondracek, R; Tan, W; Tian, L; Underwood, W	1
Cao, WL; Huang, BX; Su, HC; Sun, FK	1
Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B	1
Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H	1
Angelsen, A; Brasso, K; Christensen, IJ; Iversen, P; Johansson, JE; Tammela, TL; Thomsen, FB	1
Fujii, Y; Fukui, I; Masuda, H; Uehara, S; Yamamoto, S; Yano, A; Yonese, J; Yuasa, T	1
Dong, Y; Fang, F; Fu, Y; Jiang, Y; Wang, H; Zhang, L; Zhu, W	1
Abd Elmageed, ZY; Abdel-Mageed, AB; Ambs, S; Crawford, BE; Datta, A; Davis, R; Hudson, RS; Jia, D; Kim, H; Moparty, K; Moroz, K; Srivastav, S; Thomas, R; Yang, Y	1
Ichikawa, T; Kanai, Y; Kimura, T; Matsushima, J; Mizokami, A; Sakamoto, S; Ueda, T; Xu, M	1
Bhattacharya, S; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F	1
Agoulnik, AI; Agoulnik, IU; Coarfa, C; Frolov, A; Gandarillas, GA; Ittmann, MM; Li, R; Lopez, SM; Peterson, LE; Rajapakshe, K; Suarez, E; Weigel, NL; Zhang, M	1
Chen, Y; He, D; Li, L; Lv, W; Pei, X; Shang, H; Wang, X; Xie, H	1
Daizumoto, K; Dondoo, TO; Fukawa, T; Fukumori, T; Kanayama, HO; Kohzuki, M; Kowada, M; Kusuhara, Y; Mori, H; Nakatsuji, H; Takahashi, M	1
Chertcoff, JF; Dezanzo, P; Di Tullio, F; Ernst, G; Molina Mancero, G; Picón, X; Salvado, A	1
Chun, JY; Evans, CP; Feng, S; Gao, AC; Sun, M; Tang, Q	1
Adomat, HH; Gleave, ME; Guns, ES; Hendy, SC; Locke, JA; Nelson, CC	1
Akaza, H; Arai, Y; Hinotsu, S; Hirao, Y; Kanetake, H; Naito, S; Usami, M	1
Battaglia, M; Bettocchi, C; Ditonno, P; Fuzio, P; Lucarelli, G; Perlino, E; Selvaggi, FP	1
Dann, R; Gagnier, P; Gomella, LG; Melich, K; Sartor, O	1
Ahlgren, G; Angelsen, A; Bergh, A; Haugen, OA; Solberg, A; Tasdemir, I; Viset, T; Widmark, A	1
Brodie, AM; Goloubeva, O; Njar, VC; Sabnis, G; Schayowitz, A	1
Aozasa, K; Kawashima, A; Mukai, M; Nagahara, A; Nakai, Y; Nakayama, M; Nonomura, N; Takayama, H; Tsujimura, A	1
Cheng, H; Fazli, L; Gleave, ME; Lamoureux, F; Rennie, PS; Thomas, C; Wafa, LA	1
Eickhoff, JC; Lang, JM; Liu, G; McNeel, DG; Smith, HA; Staab, MJ; Wilding, G	1
Berger, P; Bubendorf, L; Ruiz, C; Sampson, N; Zenzmaier, C	1
Riedl, CR; Stangelberger, A; Susani, M	1
Brown, AJ; Krycer, JR	1
Carroll, K; Chodak, G; Delaere, KP; Gleason, D; Iversen, P; Klimberg, I; Kolvenbag, GJ; Lukkarinen, O; McLeod, DG; Montie, J; Persson, BE; See, WA; Tammela, TL; Tyrrell, C; Vaage, S; Wallace, DM; Wirth, MP	1
OH, WK	1
Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Cortellini, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rigatti, P; Rubagotti, A; Usai, E	1
Froehner, M; Wirth, MP	1
Albrecht, W; Collette, L; De Reijke, TM; Fava, C; Kariakine, OB; Kil, PJ; Rea, LA; Studer, UE; Whelan, P	1
Garside, L; Iversen, P; McLeod, D; Morris, T; See, W; Wirth, M	1
Iversen, P	2
Di Silverio, F; Sciarra, A	1
De Nunzio, C; Tubaro, A	1
Carroll, K; Chodak, G; Delaere, KP; Gleason, D; Iversen, P; Johansson, JE; Klimberg, I; Lundmo, P; McLeod, DG; Montie, J; Morris, T; See, WA; Tammela, TL; Tyrrell, C; Wallace, DM; Wirth, MP	1
Carroll, K; Iversen, P; McLeod, DG; Morris, T; See, WA; Wirth, MP	1
Eudy, JD; Gopalakrishnan, VK; Rothermund, CA; Vishwanatha, JK	1
Moul, JW; Ward, JF	1
Ishida, E; Konishi, N; Matsuyoshi, S; Nakamura, M; Shimada, K	1
Kirby, R	2
Chuu, CP; Dang, M; Fukuchi, J; Hiipakka, RA; Hsu, S; Kokontis, JM; Liao, S	1
Beer, TM; Garzotto, M; Janoff, DM; Mongoue-Tchokote, S; Mori, M; Peters, L; Peterson, C; Wersinger, EM	1
Armstrong, J; Iversen, P; McLeod, DG; Morris, C; Payne, H; See, WA; Tyrrell, CJ; Wirth, MP	1
Davis, NB; Ryan, CW; Stadler, WM; Vogelzang, NJ	1
Bartsch, G; Comuzzi, B; Culig, Z; Fiechtl, M; Fritzer, A; Hobisch, A; Malinowska, K; Steiner, H	1
Armstrong, J; Iversen, P; McLeod, DG; Morris, T; See, WA; Wirth, MP	1
Sternberg, CN	1
Armstrong, J; Bernstein, G; Chodak, G; Gleason, D; Klimberg, I; McLeod, DG; Montie, J; Morris, C; See, WA	1
Abascal, JM; Catalán, R; Cecchini, L; Esquena, S; Morote, J; Raventós, CX; Reventós, J; Trilla, E	1
Akdogan, B; Akyol, F; Karabulut, E; Onal, C; Ozen, H; Ozyigit, G; Selek, U	1
See, WA; Tyrrell, CJ	1
Fourcade, RO	1
Bayley, A; Bristow, R; Catton, C; Chung, P; Gospodarowicz, M; Hill, R; Menard, C; Milosevic, M; Panzarella, T; Parker, C; Toi, A; Warde, P	1
Catalán, R; Cecchini, L; Morote, J; Orsola, A; Planas, J; Raventós, CX; Trilla, E	1
de Crevoisier, R; Fizazi, K; Massard, C; Plantade, A	1
Chung, LW; Huang, C; Huang, PT; Li, S; Liang, RX; Pang, B; Wang, J; Wang, R; Zhang, H; Zhau, HE; Zhou, JG	1
Di Silverio, F; Gentile, V; Sciarra, A	1
Iversen, P; Roder, MA	1
Klotz, L	1
Brett, C; Kelly, WK; Kolvenbag, G; Liebertz, C; Mazumdar, M; Scher, HI; Schwartz, L; Schwartz, M; Shapiro, L	1
Akaza, H; Ideyama, Y; Onozawa, M; Shirai, T; Tsukamoto, S	1
Anderson, JB; Baert, L; Blackledge, GR; Carroll, K; Chamberlain, M; Gotting-Smith, K; Iversen, P; Kaisary, AV; Tammela, T; Tyrrell, CJ	1
Block, NL; Chodak, GW; Klein, EA; Kolvenbag, GJ; Patterson, AL; Sarosdy, MF; Schellenger, JJ; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ	1
Block, NL; Kelley, RP; Kolvenbag, GJ; McLeod, DG; Patterson, AL; Sarosdy, MF; Schellhammer, PF; Sharifi, R; Soloway, MS; Venner, PM; Vogelzang, NJ	1
Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G	1
Carducci, MA; Eisenberger, MA; Laufer, M; Sinibaldi, VJ	1
Anderson, JB; Carroll, K; Chamberlain, M; Iversen, P; Kaisary, AV; Melezinek, I; Tammela, TL; Tyrrell, CJ; Van Poppel, H	1
Bruchovsky, N; Crook, JM; Gleave, ME; Godwin, L; Goldenberg, SL; Hoffart, D; Klotz, LH; Sadar, M; Warkentin, M	1
Chatta, GS; Coleman, D; Crawford, ED; Eisenberger, MA; Fisher, E; Hussain, MH; Kucuk, O; Lowe, BA; Moinpour, CM; Sartor, AO	1
Borchers, TM; Delaere, KP; Hetherington, J; Heynes, CF; Morris, T; Pina, F; Ramon, J; Sánchez-Chapado, M; Stone, A; Tyrrell, C; Wallace, M; Wirth, M	1
Wirth, M	1
Furuya, Y; Fuse, H; Nagakawa, O; Nozaki, T	1
Altwein, JE; Schmidt, A	1

Reviews

8 review(s) available for bicalutamide and Disease Exacerbation

Article	Year
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. The Cochrane database of systematic reviews, 2014, Jun-30, Issue:6 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate	2014
Secondary hormonal therapies in the treatment of prostate cancer. Urology, 2002, Volume: 60, Issue:3 Suppl 1 Topics: Adrenal Cortex Hormones; Androgen Antagonists; Anilides; Biomarkers, Tumor; Disease Progression; Estrogens; Humans; Male; Megestrol Acetate; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Substance Withdrawal Syndrome; Tosyl Compounds	2002
Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program. Oncology, 2003, Volume: 65 Suppl 1 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome	2003
Bicalutamide monotherapy for early stage prostate cancer: an update. The Journal of urology, 2003, Volume: 170, Issue:6 Pt 2 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Male; Nitriles; Prognosis; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Tosyl Compounds	2003
Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Current opinion in urology, 2005, Volume: 15, Issue:3 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Cryotherapy; Disease Progression; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Salvage Therapy; Tosyl Compounds	2005
[Locally advanced prostate cancer: definition, prognosis and treatment]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Disease Progression; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Nitriles; Pelvis; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Tosyl Compounds	2007
Maximal androgen blockade for advanced prostate cancer. Best practice & research. Clinical endocrinology & metabolism, 2008, Volume: 22, Issue:2 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Humans; Male; Meta-Analysis as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Tosyl Compounds; Withholding Treatment	2008
Delaying/reducing the risk of clinical tumour progression after primary curative procedures. European urology, 2001, Volume: 40 Suppl 2 Topics: Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Disease Progression; Humans; Male; Nitriles; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds	2001

Trials

30 trial(s) available for bicalutamide and Disease Exacerbation

Article	Year
[Hormonal therapy for prostate cancer: methods and prognosis]. Zhonghua nan ke xue = National journal of andrology, 2013, Volume: 19, Issue:9 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Middle Aged; Nitriles; Prognosis; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome	2013
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis. World journal of urology, 2015, Volume: 33, Issue:9 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid	2015
Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:10 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Analysis; Survival Rate; Tosyl Compounds	2015
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. The Lancet. Oncology, 2016, Volume: 17, Issue:2 Topics: Aged; Aged, 80 and over; Anemia; Anilides; Arthralgia; Back Pain; Benzamides; Constipation; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyspnea; Fatigue; Fractures, Spontaneous; Heart Failure; Hot Flashes; Humans; Hydronephrosis; Hypertension; Male; Middle Aged; Myocardial Infarction; Nausea; Nitriles; Patient Dropouts; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds	2016
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer, 2009, Aug-01, Volume: 115, Issue:15 Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds	2009
Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. The Canadian journal of urology, 2009, Volume: 16, Issue:5 Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Azasteroids; Biomarkers, Tumor; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Neoplasm; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Tosyl Compounds; Treatment Outcome	2009
Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. International journal of radiation oncology, biology, physics, 2011, May-01, Volume: 80, Issue:1 Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality Therapy; Disease Progression; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Neoplasm, Residual; Nitriles; Odds Ratio; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds	2011
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer immunology, immunotherapy : CII, 2012, Volume: 61, Issue:7 Topics: Aged; Androgen Antagonists; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome	2012
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. The Journal of urology, 2002, Volume: 168, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds	2002
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. European urology, 2002, Volume: 42, Issue:5 Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Flutamide; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome	2002
Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program. Oncology, 2003, Volume: 65 Suppl 1 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Humans; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds; Treatment Outcome	2003
Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European urology, 2003, Volume: 44, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Disease Progression; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Factors; Survival Analysis; Tosyl Compounds	2003
Bicalutamide monotherapy for early stage prostate cancer: an update. The Journal of urology, 2003, Volume: 170, Issue:6 Pt 2 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Male; Nitriles; Prognosis; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Tosyl Compounds	2003
Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology, 2004, Volume: 63, Issue:3 Topics: Adenocarcinoma; Aged; Androgens; Anilides; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Differentiation; Chromogranin A; Chromogranins; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Lymph Node Excision; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neurosecretory Systems; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds; Triptorelin Pamoate	2004
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology, 2004, Volume: 63, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Disease Progression; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Tosyl Compounds	2004
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. The Journal of urology, 2004, Volume: 172, Issue:5 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Program Evaluation; Prospective Studies; Prostatic Neoplasms; Survival Rate; Time Factors; Tosyl Compounds	2004
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2005, Volume: 76, Issue:1 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Radiotherapy; Tosyl Compounds	2005
A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU international, 2005, Volume: 96, Issue:6 Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Imidazolidines; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Failure	2005
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU international, 2006, Volume: 97, Issue:2 Topics: Aged; Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Neoplasm Staging; Nitriles; Prostatectomy; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds	2006
The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. The Journal of urology, 2006, Volume: 176, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds	2006
The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. Journal of cancer research and clinical oncology, 2006, Volume: 132 Suppl 1 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Tosyl Compounds	2006
[Early prostate cancer 2005. New 2005 data]. Annales d'urologie, 2006, Volume: 40 Suppl 2 Topics: Anilides; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Follow-Up Studies; Humans; Male; Nitriles; Prostatic Neoplasms; Time Factors; Tosyl Compounds	2006
Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy. Urology, 2008, Volume: 71, Issue:5 Topics: Aged; Androgen Antagonists; Anilides; Cyclooxygenase Inhibitors; Disease Progression; Etoricoxib; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Pyridines; Sulfones; Tosyl Compounds	2008
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology, 1998, Volume: 51, Issue:3 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Castration; Disease Progression; Double-Blind Method; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Tosyl Compounds	1998
Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology, 1998, Volume: 52, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Flutamide; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Survival Rate; Tosyl Compounds	1998
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. The Prostate, 1999, Sep-01, Volume: 40, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Black People; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; White People	1999
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Consumer Product Safety; Disease Progression; Disease-Free Survival; Erectile Dysfunction; Flutamide; Goserelin; Humans; Italy; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Survival Rate; Tosyl Compounds	1999
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Molecular urology, 2000,Fall, Volume: 4, Issue:3 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclic AMP-Dependent Protein Kinases; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Receptors, Androgen; Signal Transduction; Testosterone; Time Factors; Tosyl Compounds	2000
Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology, 2001, Volume: 58, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diethylstilbestrol; Disease Progression; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Pain; Pain Measurement; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome	2001
Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology, 2001, Volume: 58, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Biomarkers, Tumor; Confidence Intervals; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Tosyl Compounds	2001

Other Studies

47 other study(ies) available for bicalutamide and Disease Exacerbation

Article	Year
A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure. Nagoya journal of medical science, 2019, Volume: 81, Issue:4 Topics: Aged; Anilides; Disease Progression; Flutamide; Humans; Male; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Temperature; Tosyl Compounds	2019
Gli2 mediates the development of castration‑resistant prostate cancer. International journal of oncology, 2020, Volume: 57, Issue:1 Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Nitriles; Nuclear Proteins; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Tosyl Compounds; Xenograft Model Antitumor Assays; Zinc Finger Protein Gli2	2020
Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression. Biochemical and biophysical research communications, 2021, 02-19, Volume: 541 Topics: Anilides; Cell Line, Tumor; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Male; Mitogen-Activated Protein Kinase 1; Nitriles; Prognosis; Prostatic Neoplasms; Receptors, Androgen; RNA Splicing; Splicing Factor U2AF; Tosyl Compounds	2021
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment. European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:7 Topics: Aged, 80 and over; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antigens, Surface; Brachytherapy; Disease Progression; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Goserelin; Humans; Ligands; Male; Nitriles; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Tosyl Compounds	2019
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Molecular cancer therapeutics, 2013, Volume: 12, Issue:11 Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays	2013
Targeting androgen receptor/Src complex impairs the aggressive phenotype of human fibrosarcoma cells. PloS one, 2013, Volume: 8, Issue:10 Topics: Amino Acid Sequence; Androgen Antagonists; Anilides; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Fibrosarcoma; Humans; Male; Mice; Molecular Targeted Therapy; Nitriles; Phenotype; Receptor Cross-Talk; Receptors, Androgen; src-Family Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays	2013
High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. The Prostate, 2014, Volume: 74, Issue:5 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-ets; Receptors, Androgen; Tosyl Compounds; Treatment Outcome	2014
Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. BMC research notes, 2015, Aug-05, Volume: 8 Topics: Aged; Androgen Antagonists; Anilides; Anti-Inflammatory Agents, Non-Steroidal; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds	2015
CSL regulates AKT to mediate androgen independence in prostate cancer progression. The Prostate, 2016, Volume: 76, Issue:2 Topics: Androgen Antagonists; Anilides; Animals; Cell Proliferation; Disease Progression; Humans; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Male; Mice; Mice, Nude; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Tosyl Compounds	2016
Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Apr-01, Volume: 22, Issue:7 Topics: Alternative Splicing; Androgens; Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Heterogeneous-Nuclear Ribonucleoprotein Group F-H; Humans; Male; MicroRNAs; Middle Aged; Nitriles; Nuclear Receptor Coactivator 3; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Receptors, Androgen; Response Elements; RNA Interference; Tosyl Compounds	2016
Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells. The Journal of urology, 2016, Volume: 195, Issue:5 Topics: Aged; Androgen Antagonists; Anilides; Biopsy; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Large Neutral Amino Acid-Transporter 1; Male; Nitriles; Prostate; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Neoplasm; Tosyl Compounds; Up-Regulation	2016
Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15 Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Gene Expression; Gene Knockdown Techniques; Gene Silencing; Humans; Male; Mice; Mice, Transgenic; Neoplasm Metastasis; Nitriles; Nuclear Receptor Co-Repressor 1; Prostatic Neoplasms; RNA Interference; Tosyl Compounds; Transcriptome	2016
A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy. International urology and nephrology, 2017, Volume: 49, Issue:1 Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Orchiectomy; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Serum Albumin; Time Factors; Tosyl Compounds	2017
Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. Anticancer research, 2017, Volume: 37, Issue:1 Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Blood Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Galectin 3; Galectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Nitriles; Oligonucleotide Array Sequence Analysis; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transcription, Genetic; Xenograft Model Antitumor Assays	2017
[Fatal interstitial lung disease associated with maximum androgen blockade]. Revista medica de Chile, 2016, Volume: 144, Issue:10 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antinematodal Agents; Biopsy; Disease Progression; Fatal Outcome; Humans; Lung Diseases, Interstitial; Male; Nitriles; Prostatic Neoplasms; Tomography, X-Ray Computed; Tosyl Compounds	2016
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Molecular cancer therapeutics, 2009, Volume: 8, Issue:3 Topics: Androgens; Anilides; Antineoplastic Agents; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Male; Neoplasms, Hormone-Dependent; Nitriles; Nuclear Receptor Coactivator 2; Prostatic Neoplasms; Tosyl Compounds; Tumor Cells, Cultured; Up-Regulation	2009
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. The Journal of steroid biochemistry and molecular biology, 2009, Volume: 115, Issue:3-5 Topics: Androgen Antagonists; Androgens; Anilides; Animals; Castration; Cell Line, Tumor; Cinnamates; Disease Progression; Drug Combinations; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Ketoconazole; Male; Mice; Mice, Nude; Mifepristone; Molecular Structure; Neoplasm Transplantation; Nitriles; Progesterone; Prostatic Neoplasms; Steroids; Tosyl Compounds; Transplantation, Heterologous	2009
Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer. Oncology reports, 2009, Volume: 22, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Blotting, Northern; Disease Progression; Gene Expression Regulation, Neoplastic; Goserelin; Humans; Integrin beta1; Male; Middle Aged; Nitriles; Prostatic Neoplasms; RNA, Messenger; Tosyl Compounds; Transcription, Genetic	2009
Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. British journal of cancer, 2010, Sep-28, Volume: 103, Issue:7 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; Anilides; Animals; Benzimidazoles; Castration; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Everolimus; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptor Cross-Talk; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tosyl Compounds; Xenograft Model Antitumor Assays	2010
Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU international, 2011, Volume: 107, Issue:12 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Cell Movement; Disease Progression; Epidemiologic Methods; Gonadotropin-Releasing Hormone; Humans; Macrophages; Male; Middle Aged; Nitriles; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds	2011
Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. The Prostate, 2012, Jun-01, Volume: 72, Issue:8 Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents; Apoptosis; Carbidopa; Cell Line, Tumor; Cell Survival; Disease Progression; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Treatment Outcome; Xenograft Model Antitumor Assays	2012
PAGE4 positivity is associated with attenuated AR signaling and predicts patient survival in hormone-naive prostate cancer. The American journal of pathology, 2012, Volume: 181, Issue:4 Topics: Androgens; Anilides; Animals; Antigens, Neoplasm; Cell Line, Tumor; Cell Nucleus; Disease Progression; Epithelial Cells; Gene Knockdown Techniques; Humans; Ligands; Male; Mice; Nitriles; Phosphorylation; Prostatic Neoplasms; Protein Stability; Protein Transport; Receptors, Androgen; Receptors, Glucocorticoid; Signal Transduction; Survival Analysis; Tosyl Compounds; Xenograft Model Antitumor Assays	2012
[Osteosarcoma of the prostate after radiotherapy]. Aktuelle Urologie, 2012, Volume: 43, Issue:6 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Combined Modality Therapy; Disease Progression; Fatal Outcome; Goserelin; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Transurethral Resection of Prostate	2012
Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis? PloS one, 2013, Volume: 8, Issue:1 Topics: Androgen Antagonists; Anilides; Cell Line, Tumor; Cholesterol; Disease Progression; Homeostasis; Humans; Liver X Receptors; Male; Models, Biological; Nitriles; Orphan Nuclear Receptors; Prostatic Neoplasms; Receptors, Androgen; Sterol Regulatory Element Binding Protein 2; Tosyl Compounds	2013
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. European urology, 2003, Volume: 44, Issue:5 Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Feasibility Studies; Goserelin; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome	2003
Re: See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostatic cancer. Eur Urol 2003;44:512-8. European urology, 2004, Volume: 45, Issue:5 Topics: Anilides; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tosyl Compounds	2004
Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. BMC urology, 2005, Mar-24, Volume: 5 Topics: Anilides; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds	2005
Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. The Journal of pathology, 2005, Volume: 206, Issue:4 Topics: Aged; Androgen Antagonists; Anilides; Apoptosis; Arabidopsis Proteins; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Cell Survival; Cells, Cultured; Disease Progression; Drug Therapy, Combination; Epithelial Cells; Fatty Acid Desaturases; Gonadotropin-Releasing Hormone; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Proteins; Nitriles; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds	2005
Case study: management of advanced prostate cancer with soft tissue metastases. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:3 Topics: Adenocarcinoma; Anilides; Disease Progression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Risk; Soft Tissue Neoplasms; Time Factors; Tomography, X-Ray Computed; Tosyl Compounds; Treatment Outcome	2005
Case study: management of lymph node-positive disease detected at radical prostatectomy. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:3 Topics: Adenocarcinoma; Aged; Anilides; Biopsy; Disease Progression; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Metastasis; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prunus; Quality of Life; Tosyl Compounds; Vitamin B Complex	2005
Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. The Prostate, 2005, Dec-01, Volume: 65, Issue:4 Topics: Androgen Antagonists; Androgens; Anilides; Animals; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Disease Progression; Humans; Intracellular Signaling Peptides and Proteins; Male; Metribolone; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Testosterone; Tosyl Compounds	2005
Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU international, 2005, Volume: 96, Issue:4 Topics: Adenocarcinoma; Age Factors; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Follow-Up Studies; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Tosyl Compounds; Treatment Failure	2005
The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide. The Prostate, 2006, Mar-01, Volume: 66, Issue:4 Topics: Androgen Antagonists; Anilides; Blotting, Western; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Tumor Cells, Cultured; Up-Regulation	2006
Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. BJU international, 2006, Volume: 97, Issue:3 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Humans; Male; Nitriles; Prostatic Neoplasms; Survival Analysis; Tosyl Compounds	2006
The third analysis of the bicalutamide Early Prostate Cancer programme. BJU international, 2006, Volume: 97, Issue:3 Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Humans; Male; Nitriles; Prostatic Neoplasms; Tosyl Compounds	2006
Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urologia internationalis, 2006, Volume: 77, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Cross-Sectional Studies; Delayed-Action Preparations; Disease Progression; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Testosterone; Tosyl Compounds; Treatment Failure	2006
Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer. Journal of the National Medical Association, 2006, Volume: 98, Issue:7 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Tosyl Compounds; Triptorelin Pamoate	2006
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer research, 2007, Jul-01, Volume: 67, Issue:13 Topics: Aged; Aged, 80 and over; Androgens; Anilides; Disease Progression; Humans; Hypoxia; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Oxygen; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Treatment Outcome	2007
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. The Journal of urology, 2007, Volume: 178, Issue:4 Pt 1 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone; Tosyl Compounds	2007
PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer research, 2007, Sep-15, Volume: 67, Issue:18 Topics: Androgen Antagonists; Anilides; Animals; Cell Line, Tumor; Disease Progression; DNA, Antisense; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; NIH 3T3 Cells; Nitriles; Oncogene Protein v-akt; Phosphoric Diester Hydrolases; Prostatic Neoplasms; Pyrophosphatases; Signal Transduction; Tosyl Compounds; Transfection	2007
The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert review of anticancer therapy, 2008, Volume: 8, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Program Evaluation; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds	2008
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Bone and Bones; Bone Neoplasms; Disease Progression; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Tosyl Compounds	1997
A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer, 1998, Feb-01, Volume: 82, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adenocarcinoma; Aminobiphenyl Compounds; Androgen Antagonists; Anilides; Animals; Carcinogens; Disease Progression; Enzyme Inhibitors; Finasteride; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Testosterone; Tosyl Compounds	1998
Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer. Urology, 1999, Volume: 54, Issue:4 Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Disease Progression; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds	1999
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. The Journal of urology, 2000, Volume: 164, Issue:5 Topics: Androgen Antagonists; Anilides; Castration; Disease Progression; Follow-Up Studies; Humans; Male; Multicenter Studies as Topic; Nitriles; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Tosyl Compounds	2000
Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer. Endocrine journal, 2002, Volume: 49, Issue:1 Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Bone Neoplasms; Chlormadinone Acetate; Diethylstilbestrol; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Statistics, Nonparametric; Testosterone; Tosyl Compounds	2002
Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration. Urologia internationalis, 2002, Volume: 68, Issue:4 Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Goserelin; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Time Factors; Tosyl Compounds	2002